CS585: A selective IP agonist
The company’s third asset, CS585, is in the earlier stages of development and, while it has not yet been assigned a specific target indication, it is backed by preclinical research showing promise in thrombosis prevention without increased risk of bleeding. The candidate is an oral, selective and potent agonist of the prostacyclin receptor (IP).
During the CMD, the potential of CS585 to address rare disease was discussed by Dr. Michael Holinstat, associate professor at the University of Michigan Medical School and Cereno’s director of translational research. In the presentation, Dr. Holinstat highlighted how antiplatelet therapies have reduced the risk of morbidity and mortality by >26%, but noted that morbidity and mortality due to cardiovascular events remain unacceptably high. The challenge stems from novel antiplatelet therapies that need to decrease both platelet activation and thrombosis, while also limiting the risk of bleeding and intracranial haemorrhage. Notably, CS585 as an IP agonist has been shown to inhibit the aggregation of platelets from multiple pathways and, encouragingly, preclinical data have shown that this translates to the inhibition of clots (Exhibits 7 and 8). In addition, CS585 appears to target the IP receptor more selectively than existing IP agonists, according to Dr. Holinstat, who highlighted that these competitors are also challenged by short half-lives and by their utility in the blood, hindering their clinical application to indications such as pulmonary hypertension.

CS014: A ‘rare’ pivot
A key highlight of the CMD was Cereno’s announcement of its decision to pursue development of CS014, the second HDACi in its portfolio and a valproic acid (VPA) analogue (with a similar pharmacology profile to CS1), in the rare disease IPF, versus the broad label of thrombosis previously. We believe the decision was driven by a combination of factors, including clinical, commercial and strategic. Cereno recently presented encouraging preclinical data for CS014, which, although it related to a PAH model, demonstrated a robust, reversal of fibrosis and dose-dependent reverse remodelling of pulmonary vasculature, including plexiform lesions and small vessel-related fibrosis, which are also key pathological features of IPF. As part of the CMD, management also presented previously reported scientific publications and preclinical data. Preclinical data were also presented on CS014’s ability to reduce fibrosis and thrombosis (discussed in further detail below).

CS1: Advancing towards pivotal studies in PAH
CS1, Cereno’s lead asset, is a histone deacetylase HDAC inhibitor (HDACi), which aims to leverage the principles of epigenetic modulation to achieve disease modification in PAH. As part of the CMD presentation, Dr. Raymond Benza, system director of pulmonary hypertension at Mount Sinai Icahn School of Medicine, highlighted the epidemiology of PAH and the significant unmet need for safe, effective and disease-modifying treatments. This was followed by the Cereno team discussing the CS1 programme in PAH, the recently announced positive Phase IIa data and the forthcoming development plans for the asset.

BioStock: Cereno Scientifics vd om nya behandlingar för sällsynta sjukdomar
I dag kl. 08:34 ∙ Cision
BioStock träffade Cereno Scientifics vd Sten R. Sörensen på BioEurope. Cereno utvecklar nya behandlingar för sällsynta sjukdomar i syfte att förbättra och förlänga livet för patienter som har stor brist på tillräckliga behandlingsalternativ. I den här intervjun delar Sten med sig av insikter om bolagets aktuella projekt, deras mål på BioEurope och vad framtiden har att erbjuda. Se intervjun med Cereno Scientific på biostock.se:
https://www.biostock.se/2024/11/cereno-scientifics-vd-om-nya-behandlingar-for-sallsynta-sjukdomar/

Detta är ett pressmeddelande från BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Cereno Scientifics vd om nya behandlingar för sällsynta sjukdomar

https://www.youtube.com/watch?v=lQ3Y1yiYmQE

"Wrapping up the final day at BIO Europe 2024 in Stockholm! Our CEO Sten R. Sörensen, CMO & Head of R&D Dr. Rahul Agrawal, and Director of Business Development Julia Fransson have had an inspiring and productive experience filled with **meaningful discussions with potential partners, investors, and industry peers.**"

Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech company developing innovative treatments for diseases with high unmet medical needs, today announced that the Company has entered into a financing agreement (the “Financing Agreement”) securing loan financing of at least 250 MSEK. The Financing Agreement includes a cash loan in two tranches totaling 175 MSEK as well as the issue of convertible loans of 75 MSEK with Fenja Capital II A/S and the US-based investor Arena Investors, LP (the “Financiers”). The Financing Agreement secures the financial runway for Cereno Scientific to reach its set milestones into 2026.

For en deilig nyhet med lån og konvertering på 6kr tallet når vi ligge på 5kr, og ikke 3 måneder seigpining med emisjon og tegning retter .

Insidehandel på nesten 140T aksjer til en verdi av ca 700tusen sek de siste dagene er beget bra. Ingen der som legger sparepengene sine i noe de ikke har tro på.